Investigadores españoles eliminan, por primera vez, el cáncer de páncreas en ratones
Investigadores del Centro Nacional de Investigaciones Oncológicas, liderados por Mariano Barbacid, lograron eliminar por primera vez el cáncer de páncreas más agresivo en ratones mediante una terapia combinada de tres fármacos, sin efectos secundarios relevantes y evitando resistencias al tratamiento
TL;DR
- A triple-drug therapy developed by CNIO researchers has cured aggressive pancreatic cancer in mice.
- The therapy targets KRAS, EGFR, and STAT3 proteins, which are crucial for tumor growth and resistance.
- The treatment showed no significant side effects and prevented the development of drug resistance in mice.
- Previous attempts by the same team in 2019 showed partial success but were limited by tumor size and incomplete response.
- The new therapy uses daraxorasib (a KRAS inhibitor), afatinib, and a protein degrader (SD36).
- Further research is planned to refine the therapy, test it on other mouse models, study its effects on metastasis and the tumor microenvironment, and secure funding for human clinical trials.
- The CRIS Cancer Foundation has been a significant funder of this research.